DK1252192T3 - Forbedring af antistofbaserede fusionsproteiners serumhalveringstid - Google Patents
Forbedring af antistofbaserede fusionsproteiners serumhalveringstidInfo
- Publication number
- DK1252192T3 DK1252192T3 DK01916083T DK01916083T DK1252192T3 DK 1252192 T3 DK1252192 T3 DK 1252192T3 DK 01916083 T DK01916083 T DK 01916083T DK 01916083 T DK01916083 T DK 01916083T DK 1252192 T3 DK1252192 T3 DK 1252192T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- life
- based fusion
- fusion proteins
- enhancement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18176800P | 2000-02-11 | 2000-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1252192T3 true DK1252192T3 (da) | 2006-11-20 |
Family
ID=22665708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01916083T DK1252192T3 (da) | 2000-02-11 | 2001-02-09 | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7091321B2 (enExample) |
| EP (1) | EP1252192B1 (enExample) |
| JP (2) | JP5179689B2 (enExample) |
| CN (1) | CN1406249B (enExample) |
| AT (1) | ATE336514T1 (enExample) |
| AU (1) | AU4314801A (enExample) |
| CA (1) | CA2399832C (enExample) |
| CY (1) | CY1105725T1 (enExample) |
| DE (1) | DE60122286T2 (enExample) |
| DK (1) | DK1252192T3 (enExample) |
| ES (1) | ES2269366T3 (enExample) |
| HU (1) | HUP0204475A2 (enExample) |
| MX (1) | MXPA02007733A (enExample) |
| NO (1) | NO20023774D0 (enExample) |
| PT (1) | PT1252192E (enExample) |
| WO (1) | WO2001058957A2 (enExample) |
Families Citing this family (308)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| US7387772B1 (en) * | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR20020018197A (ko) * | 1999-05-19 | 2002-03-07 | 추후보정 | Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| CZ2003214A3 (cs) * | 2000-06-29 | 2003-08-13 | Merck Patent Gmbh | Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu |
| US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| BR0209177A (pt) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| SI1471974T1 (sl) * | 2002-02-06 | 2007-12-31 | Ares Trading Sa | Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| WO2004021861A2 (en) * | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| KR101163424B1 (ko) | 2003-12-30 | 2012-07-13 | 메르크 파텐트 게엠베하 | Ｉｌ－７ 융합 단백질 |
| EP1699821B1 (en) * | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| CA2553883C (en) * | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| AU2005277641A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| CN100429233C (zh) * | 2005-02-03 | 2008-10-29 | 上海长海医院 | 一种重组融合蛋白及其制备方法及用途 |
| PT1853718E (pt) | 2005-02-15 | 2015-11-12 | Univ Duke | Anticorpos anti-cd19 e usos em oncologia |
| US20060263357A1 (en) | 2005-05-05 | 2006-11-23 | Tedder Thomas F | Anti-CD19 antibody therapy for autoimmune disease |
| CA2606102C (en) * | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| WO2007005612A2 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| AU2006304387A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP2500360B1 (en) * | 2005-10-31 | 2015-08-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| SI1966238T1 (sl) * | 2005-12-30 | 2012-08-31 | Merck Patent Gmbh | Variante interlevkina-12P40 z izboljšano stabilnostjo |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US7932055B2 (en) | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
| DE602006016765D1 (de) | 2006-06-30 | 2010-10-21 | Conaris Res Inst Ag | Verbesserte sgp 130Fc Dimere |
| JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| AR062709A1 (es) * | 2006-09-08 | 2008-11-26 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| CN105175553B (zh) * | 2007-05-30 | 2019-11-22 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| CN101687933B (zh) * | 2007-05-30 | 2015-11-25 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| AR067537A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
| CL2008002054A1 (es) * | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| AR067584A1 (es) * | 2007-07-20 | 2009-10-14 | Hoffmann La Roche | Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| MX2010006735A (es) | 2007-12-21 | 2010-09-30 | Medimmune Ltd | Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173. |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| KR20100107501A (ko) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| CA2715043C (en) * | 2008-02-05 | 2021-02-16 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
| CN102066575A (zh) * | 2008-04-18 | 2011-05-18 | 雅培制药有限公司 | 结合蛋白体内半衰期的体外估测 |
| EP2331136B1 (en) | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| US8775090B2 (en) | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
| BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| EP2722055A1 (en) | 2009-08-17 | 2014-04-23 | Tracon Pharmaceuticals, Inc. | Combination therapy with antibodies and anti-VEGF agents for the treatment of cancer |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| MX2012004029A (es) | 2009-10-07 | 2012-05-08 | Macrogenics Inc | Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso. |
| EP2507267B1 (en) * | 2009-12-02 | 2016-09-14 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins |
| EP4382170A3 (en) | 2009-12-06 | 2024-09-04 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| SG10201503351RA (en) * | 2010-01-19 | 2015-06-29 | Harvard College | Engineered Opsonin for Pathogen Detection and Treatment |
| AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
| CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| MX375112B (es) | 2010-07-09 | 2025-03-06 | Biogen Hemophilia Inc | Polipéptidos de factor ix y métodos para usarlos. |
| JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
| ES2500048T3 (es) | 2010-09-14 | 2014-09-29 | F. Hoffmann-La Roche Ag | Procedimiento para purificar eritropoyetina pegilada |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| AU2012280474A1 (en) | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2012283235A1 (en) | 2011-07-08 | 2014-01-09 | Bayer Intellectual Property Gmbh | Fusion proteins releasing Relaxin and uses thereof |
| EP4169525A1 (en) | 2011-07-08 | 2023-04-26 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
| EA028914B1 (ru) | 2011-07-25 | 2018-01-31 | Байоджен Хемофилия Инк. | Исследования для мониторинга нарушений свертываемости крови |
| DK2760471T3 (en) | 2011-09-30 | 2017-05-08 | Dana Farber Cancer Inst Inc | THERAPEUTIC PEPTIDES |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| CN103906533A (zh) | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| EA038705B1 (ru) | 2012-01-12 | 2021-10-07 | Биовератив Терапьютикс Инк. | Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| PL2822575T3 (pl) * | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| SI3495387T1 (sl) | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| SG11201408530YA (en) * | 2012-08-02 | 2015-03-30 | Hoffmann La Roche | Method for producing monomeric and multimeric molecules and uses thereof |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| AU2013331000B2 (en) | 2012-10-18 | 2018-04-19 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| JP2015536933A (ja) | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法 |
| WO2014070953A1 (en) | 2012-10-30 | 2014-05-08 | Biogen Idec Ma Inc. | Methods of Using FVIII Polypeptide |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| EP2956468B1 (en) | 2013-02-12 | 2020-06-10 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| US10065987B2 (en) | 2013-02-12 | 2018-09-04 | Bristol-Myers Squibb Company | High pH protein refolding methods |
| MY186864A (en) | 2013-03-12 | 2021-08-26 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| WO2014144791A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| CA2904357C (en) | 2013-03-15 | 2020-09-22 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| ES2926798T3 (es) | 2013-03-15 | 2022-10-28 | Bioverativ Therapeutics Inc | Formulaciones de polipéptido de factor VIII |
| JP2016518361A (ja) | 2013-04-19 | 2016-06-23 | シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ | 血管漏出症候群の発生を抑制するサイトカイン治療 |
| US9963515B2 (en) | 2013-04-29 | 2018-05-08 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| EP3848045A1 (en) | 2013-05-21 | 2021-07-14 | President and Fellows of Harvard College | Engineered heme-binding compositions and uses thereof |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| MX371187B (es) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos. |
| US10325687B2 (en) | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US10513546B2 (en) | 2013-12-18 | 2019-12-24 | President And Fellows Of Harvard College | CRP capture/detection of gram positive bacteria |
| CN106103476B (zh) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3116903A2 (en) | 2014-03-14 | 2017-01-18 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
| EA202092926A3 (ru) | 2014-03-24 | 2021-10-29 | Биовератив Терапьютикс Инк. | Лиофилизированные составы, содержащие фактор ix |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| WO2016011035A2 (en) | 2014-07-15 | 2016-01-21 | Medlmmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| ES2826566T3 (es) | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| KR20240131465A (ko) | 2014-12-01 | 2024-08-30 | 훼링 비.브이. | 선택적 il-6-트랜스-신호전달 억제제 조성물 |
| EP3226888B1 (en) | 2014-12-01 | 2021-04-21 | Ferring B.V. | Administration of a selective il-6-trans-signalling inhibitor |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| MX386491B (es) | 2015-03-09 | 2025-03-18 | argenx BV | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| AU2016271111B2 (en) | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| US10435457B2 (en) | 2015-08-06 | 2019-10-08 | President And Fellows Of Harvard College | Microbe-binding molecules and uses thereof |
| UA128469C2 (uk) | 2015-10-08 | 2024-07-24 | Макродженікс, Інк. | Спосіб лікування в7-н3-експресуючого раку |
| MX2018006072A (es) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| AU2017228470A1 (en) | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| AU2017234679A1 (en) | 2016-03-16 | 2018-08-30 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| US10968279B2 (en) | 2016-05-09 | 2021-04-06 | Bristol-Myers Squibb Company | TL1A antibodies and uses thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018011381A1 (en) | 2016-07-15 | 2018-01-18 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
| JP7573365B2 (ja) | 2016-08-12 | 2024-10-25 | メルク パテント ゲーエムベーハー | 癌の併用療法 |
| WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| AU2017363309A1 (en) | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| CA3044838A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MD3558391T2 (ro) | 2016-12-23 | 2022-05-31 | Immunogen Inc | Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora |
| BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics, Inc. | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
| TW201825515A (zh) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Ｍｅｔ抗體以及其免疫結合物及用途 |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| EP3600429B1 (en) * | 2017-03-20 | 2023-10-25 | Bio-Techne Corporation | Il-37 fusion protein and methods of making and using same |
| WO2018213097A1 (en) | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
| MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| US12139533B2 (en) | 2017-12-20 | 2024-11-12 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-CD200 antibodies |
| JP7358361B2 (ja) | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| CN111699004A (zh) | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| SG11202008593PA (en) | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| CR20250022A (es) | 2018-04-02 | 2025-02-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450) |
| CA3096703A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| MX2020013466A (es) | 2018-06-26 | 2021-04-19 | Immunogen Inc | Inmunoconjugados dirigidos a adam9 y métodos para usarlos. |
| MY201995A (en) | 2018-07-09 | 2024-03-28 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| KR102884523B1 (ko) | 2018-10-03 | 2025-11-10 | 젠코어 인코포레이티드 | IL-12 이종이량체 Fc-융합 단백질 |
| EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CN119033684A (zh) | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| CA3117429A1 (en) | 2018-11-01 | 2020-05-07 | Merck Patent Gmbh | Anti-tim-3 antibodies |
| AU2019372436A1 (en) | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Methods of administering anti-TIM-3 antibodies |
| JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル－マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
| US12428484B2 (en) | 2018-12-06 | 2025-09-30 | Alexion Pharmaceuticals, Inc. | Anti-ALK2 antibodies and uses thereof |
| US20220056135A1 (en) | 2018-12-21 | 2022-02-24 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| CN113573782B (zh) | 2018-12-21 | 2025-12-16 | Ose免疫疗法公司 | 针对人pd-1的双功能分子 |
| AU2019406452B2 (en) | 2018-12-21 | 2021-09-16 | Ose Immunotherapeutics | Humanized anti-human-PD-1 antibody |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| CN118894938A (zh) | 2019-01-22 | 2024-11-05 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| EP3969119A1 (en) | 2019-05-17 | 2022-03-23 | Xencor, Inc. | Il-7-fc-fusi0n proteins |
| BR112021024632A2 (pt) | 2019-06-07 | 2022-01-18 | Argenx Bvba | Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea |
| WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| EP3999541A1 (en) | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
| CN114555634B (zh) | 2019-08-13 | 2025-01-10 | 美国安进公司 | 用于扩增调节性t细胞的白介素-2突变蛋白 |
| CA3149719A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| EP4037700A2 (en) | 2019-10-03 | 2022-08-10 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| JP7745556B2 (ja) | 2020-02-21 | 2025-09-29 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７結合分子及びその使用 |
| WO2021202235A1 (en) | 2020-04-01 | 2021-10-07 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
| US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| US20240279353A1 (en) | 2020-07-06 | 2024-08-22 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US11919945B2 (en) | 2020-11-04 | 2024-03-05 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies |
| CA3202233A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic BioPharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
| AU2021402065A1 (en) | 2020-12-17 | 2023-06-29 | Boehringer Ingelheim International Gmbh | Bifunctional anti-pd1/il-7 molecules |
| WO2022127793A1 (zh) | 2020-12-18 | 2022-06-23 | 珠海泰诺麦博生物技术有限公司 | 呼吸道合胞病毒特异性结合分子 |
| EP4277926A1 (en) | 2021-01-15 | 2023-11-22 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022307460A1 (en) * | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| US20230201364A1 (en) * | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| EP4469159A1 (en) | 2022-01-27 | 2024-12-04 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| CN119630428A (zh) | 2022-07-12 | 2025-03-14 | 西托姆克斯治疗公司 | Epcam免疫缀合物及其用途 |
| EP4558529A1 (en) | 2022-07-22 | 2025-05-28 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| KR20250167153A (ko) | 2023-03-03 | 2025-11-28 | 셀덱스 쎄라퓨틱스, 인크. | 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물 |
| EP4688851A1 (en) | 2023-03-27 | 2026-02-11 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| US20250109187A1 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 |
| CN122422333A (zh) | 2023-10-17 | 2026-07-17 | 百时美施贵宝公司 | Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途 |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| WO2025133694A1 (en) | 2023-12-20 | 2025-06-26 | argenx BV | Fcrn/hsa-binding molecules and methods of use |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025155877A2 (en) | 2024-01-18 | 2025-07-24 | The Regents Of The University Of California | Antibodies binding to pad4 and uses thereof |
| WO2025174974A1 (en) | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US20260092096A1 (en) | 2024-05-14 | 2026-04-02 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025245176A1 (en) | 2024-05-22 | 2025-11-27 | Bristol-Myers Squibb Company | Multispecific antibody constructs |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| US20250376536A1 (en) | 2024-06-06 | 2025-12-11 | Bristol-Myers Squibb Company | Multispecific anti-cd40 / anti-fap antibodies and uses thereof |
| TW202607016A (zh) | 2024-06-06 | 2026-02-16 | 美商必治妥美雅史谷比公司 | 抗fap抗體及其用途 |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| WO2026068750A1 (en) | 2024-09-27 | 2026-04-02 | Biomunex Pharmaceuticals | Antibodies that specifically bind mucosal associated invariant t (mait) cells |
| WO2026096695A1 (en) | 2024-10-31 | 2026-05-07 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
| US20260144884A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibody drug conjugates |
| US20260144885A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibodies and uses thereof |
| WO2026128221A1 (en) | 2024-12-12 | 2026-06-18 | University Of Rochester | Antt-tgfbp3 antibodies to treat cancer and sarcopenia |
| WO2026143022A1 (en) | 2024-12-23 | 2026-07-02 | Point Loma Nazarene University | Antibody directed enzyme pro-drug therapy (adept) for cancer treatment using an antibody or fragment that binds to a cd206 receptor and 3-cyclopentyl-alpha-phenylalanine-methotrexate |
| WO2026150085A1 (en) | 2025-01-10 | 2026-07-16 | argenx BV | Igg-binding molecules and methods of use thereof |
| WO2026161794A1 (en) | 2025-01-27 | 2026-07-30 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and therapeutic uses thereof |
Family Cites Families (227)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
| EP0158198A1 (en) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA and use thereof |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
| US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
| US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
| JPS63267278A (ja) | 1986-03-14 | 1988-11-04 | Toray Ind Inc | インタ−フエロン結合体を暗号化する塩基配列 |
| EP0237019A3 (en) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DK173067B1 (da) * | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
| US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
| PH26813A (en) | 1987-09-02 | 1992-11-05 | Ciba Geigy Ag | Conjugates of cytokines with immunoglobulins |
| CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
| NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
| US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
| DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues |
| US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US6750329B1 (en) | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| DE69019609T2 (de) | 1989-07-07 | 1995-11-30 | Takeda Chemical Industries Ltd | Proteine und deren Herstellung. |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| DE69034022T2 (de) | 1989-09-20 | 2003-07-10 | Abbott Laboratories, Abbott Park | Verfahren zur Herstellung von Fusionsproteinen |
| AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| DK0433827T3 (da) | 1989-12-22 | 1998-09-28 | Hoffmann La Roche | Cytotoksisk lumfocytmodningsfaktor |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0517754A1 (en) | 1990-03-02 | 1992-12-16 | Repligen Corporation | Antibody constructs with enhanced binding affinity |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| EP0541716A1 (en) | 1990-07-27 | 1993-05-19 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| WO1992008801A1 (en) | 1990-11-09 | 1992-05-29 | Abbott Laboratories | Bridging antibody fusion constructs |
| DK0561907T3 (da) | 1990-12-05 | 1999-05-31 | Novo Nordisk As | Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
| AU666866B2 (en) | 1991-08-30 | 1996-02-29 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
| US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
| US5376367A (en) | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
| US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| AU687733B2 (en) | 1992-04-01 | 1998-03-05 | Rockefeller University, The | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| DE4228839A1 (de) * | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| EP1757695A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| KR960701988A (ko) | 1993-04-20 | 1996-03-28 | 윌리엄 에스. 로빈슨 | 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents) |
| WO1994024160A2 (en) | 1993-04-21 | 1994-10-27 | Brigham And Women's Hospital | Erythropoietin muteins with enhanced activity |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| WO1994025609A1 (en) | 1993-04-28 | 1994-11-10 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
| KR960701650A (ko) | 1993-04-29 | 1996-03-28 | 찰스 엠. 브룩 | 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods) |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| DE69521789T2 (de) | 1994-02-01 | 2002-04-25 | The United States Of Amerika Represented By The Secretary, Department Of Health And Human | Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten |
| WO1995028427A1 (en) | 1994-04-15 | 1995-10-26 | Imclone Systems Incorporated | Chimeric interleukin-3/mutein interleukin-6 lymphokine |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| CN1636594B (zh) | 1994-04-26 | 2012-08-29 | 儿童医学中心公司 | 血管生成抑制素和用于抑制血管生成的方法 |
| DK0759944T3 (da) | 1994-05-13 | 2001-11-26 | Biovation Ltd | Forbedringer af og relateret til peptidfremføring |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| CZ25697A3 (en) | 1994-07-29 | 1997-09-17 | Smithkline Beecham Plc | Novel compounds |
| US5888773A (en) | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| PT706799E (pt) | 1994-09-16 | 2002-05-31 | Merck Patent Gmbh | Imunoconjugados ii |
| CA2205572A1 (en) * | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| EP0815224B1 (en) | 1995-03-10 | 2004-07-21 | Genentech, Inc. | Receptor activation by gas6 |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| AU5539596A (en) | 1995-04-06 | 1996-10-23 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| AU5893796A (en) | 1995-06-07 | 1996-12-30 | Novo Nordisk A/S | Modification of polypeptides |
| WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| AU695934B2 (en) | 1995-06-30 | 1998-08-27 | Eli Lilly And Company | Methods for treating diabetes |
| US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
| EP0857210B1 (en) | 1995-10-23 | 2003-09-03 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| AU1407997A (en) | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
| IL124831A0 (en) | 1995-12-27 | 1999-01-26 | Genentech Inc | Ob protein derivatives having prolonged half-life |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
| US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| AU2527397A (en) | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| WO1998000127A1 (en) | 1996-07-02 | 1998-01-08 | Bar-Ilan University | Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| WO1998006752A1 (en) | 1996-08-16 | 1998-02-19 | The Rockefeller University | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| EP1835030A1 (en) | 1996-12-20 | 2007-09-19 | Amgen, Inc. | OB fusion protein compositions and methods |
| US6737057B1 (en) | 1997-01-07 | 2004-05-18 | The University Of Tennessee Research Corporation | Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2284726A1 (en) | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
| IL132380A0 (en) | 1997-04-17 | 2001-03-19 | Amgen Inc | Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
| WO1999002709A1 (en) | 1997-07-10 | 1999-01-21 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| BR9908226A (pt) * | 1998-02-25 | 2000-10-24 | Lexigen Pharm Corp | Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo |
| US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| CN1318092C (zh) | 1998-04-15 | 2007-05-30 | 利思进药品公司 | 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物 |
| HK1038881A1 (zh) | 1998-04-17 | 2002-04-04 | 利思进药品公司 | 通过共同给予前列腺素抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答 |
| AU3655899A (en) * | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
| WO1999058662A1 (fr) | 1998-05-14 | 1999-11-18 | Merck Patent Gmbh | Proteine fusionnee |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| CA2331370A1 (en) | 1998-06-03 | 1999-12-09 | The Children's Medical Center Corporation | Protein oligomer compositions comprising endostatin protein and methods of using the same |
| DK1088084T3 (da) | 1998-06-15 | 2007-01-29 | Gtc Biotherapeutics Inc | Erythropoietin analog-humant serumalbumin fusionsprotein |
| GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| JP2002523036A (ja) | 1998-08-25 | 2002-07-30 | レキシジェン ファーマシューティカルズ コーポレイション | イムノフュージンとしての新脈管形成インヒビターの発現および輸送 |
| US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
| US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
| DE69935345T3 (de) | 1998-10-23 | 2018-03-01 | Amgen Inc. | Methoden und zusammensetzungen zur prävention und behandlung der anämie |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| MXPA01006922A (es) | 1999-01-07 | 2002-04-24 | Lexigen Pharm Corp | Expresion y exportacion de proteinas de anti-obesidad como proteinas de fusion en fc. |
| KR100773109B1 (ko) | 1999-05-06 | 2007-11-02 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
| EP1177285A1 (en) | 1999-05-07 | 2002-02-06 | Genentech, Inc. | Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| KR20020018197A (ko) | 1999-05-19 | 2002-03-07 | 추후보정 | Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
| WO2000078334A1 (en) | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| US8623373B2 (en) | 2000-02-24 | 2014-01-07 | Philogen S.P.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| NZ522320A (en) | 2000-05-12 | 2007-03-30 | Neose Technologies Inc | In vitro modification of glycosylation patterns of recombinant glycopeptides |
| CZ2003214A3 (cs) | 2000-06-29 | 2003-08-13 | Merck Patent Gmbh | Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu |
| WO2002057435A2 (en) | 2001-01-18 | 2002-07-25 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
| PL362324A1 (en) | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| BR0209177A (pt) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| CA2456470A1 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| US20050069521A1 (en) | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| EP1673395A1 (en) * | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| KR101163424B1 (ko) | 2003-12-30 | 2012-07-13 | 메르크 파텐트 게엠베하 | Ｉｌ－７ 융합 단백질 |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| SI1966238T1 (sl) | 2005-12-30 | 2012-08-31 | Merck Patent Gmbh | Variante interlevkina-12P40 z izboljšano stabilnostjo |
| CN101346395A (zh) | 2005-12-30 | 2009-01-14 | 默克专利有限公司 | 阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体 |
| AU2006332155B2 (en) | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| US7622522B2 (en) | 2007-09-27 | 2009-11-24 | Sabic Innovative Plastics Ip B.V. | Flame-retardant poly(arylene ether) composition and its use as a covering for coated wire |
-
2001
- 2001-02-09 JP JP2001558103A patent/JP5179689B2/ja not_active Expired - Fee Related
- 2001-02-09 WO PCT/US2001/004455 patent/WO2001058957A2/en not_active Ceased
- 2001-02-09 PT PT01916083T patent/PT1252192E/pt unknown
- 2001-02-09 HU HU0204475A patent/HUP0204475A2/hu unknown
- 2001-02-09 CA CA2399832A patent/CA2399832C/en not_active Expired - Lifetime
- 2001-02-09 AU AU4314801A patent/AU4314801A/xx active Pending
- 2001-02-09 EP EP01916083A patent/EP1252192B1/en not_active Expired - Lifetime
- 2001-02-09 MX MXPA02007733A patent/MXPA02007733A/es active IP Right Grant
- 2001-02-09 DE DE60122286T patent/DE60122286T2/de not_active Expired - Lifetime
- 2001-02-09 US US09/780,668 patent/US7091321B2/en not_active Expired - Lifetime
- 2001-02-09 ES ES01916083T patent/ES2269366T3/es not_active Expired - Lifetime
- 2001-02-09 CN CN018058639A patent/CN1406249B/zh not_active Expired - Lifetime
- 2001-02-09 AT AT01916083T patent/ATE336514T1/de active
- 2001-02-09 DK DK01916083T patent/DK1252192T3/da active
-
2002
- 2002-08-09 NO NO20023774A patent/NO20023774D0/no not_active Application Discontinuation
-
2005
- 2005-11-07 US US11/268,191 patent/US7507406B2/en not_active Expired - Lifetime
-
2006
- 2006-10-24 CY CY20061101528T patent/CY1105725T1/el unknown
-
2009
- 2009-01-27 US US12/360,682 patent/US7790415B2/en not_active Expired - Fee Related
-
2012
- 2012-05-10 JP JP2012108394A patent/JP5572665B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012176969A (ja) | 2012-09-13 |
| CA2399832A1 (en) | 2001-08-16 |
| EP1252192A2 (en) | 2002-10-30 |
| DE60122286D1 (de) | 2006-09-28 |
| JP5572665B2 (ja) | 2014-08-13 |
| HUP0204475A2 (en) | 2003-04-28 |
| US7790415B2 (en) | 2010-09-07 |
| WO2001058957A3 (en) | 2002-05-02 |
| US7507406B2 (en) | 2009-03-24 |
| JP5179689B2 (ja) | 2013-04-10 |
| US20090264627A1 (en) | 2009-10-22 |
| DE60122286T2 (de) | 2007-08-02 |
| MXPA02007733A (es) | 2004-09-10 |
| CN1406249A (zh) | 2003-03-26 |
| PT1252192E (pt) | 2007-01-31 |
| US7091321B2 (en) | 2006-08-15 |
| JP2003522200A (ja) | 2003-07-22 |
| ATE336514T1 (de) | 2006-09-15 |
| CY1105725T1 (el) | 2010-12-22 |
| US20060034836A1 (en) | 2006-02-16 |
| CN1406249B (zh) | 2010-06-16 |
| NO20023774L (no) | 2002-08-09 |
| CA2399832C (en) | 2011-09-20 |
| WO2001058957A2 (en) | 2001-08-16 |
| NO20023774D0 (no) | 2002-08-09 |
| EP1252192B1 (en) | 2006-08-16 |
| AU4314801A (en) | 2001-08-20 |
| ES2269366T3 (es) | 2007-04-01 |
| US20020147311A1 (en) | 2002-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20023774D0 (no) | Ökning av antistoffbaserte fusjonsproteiners halveringstid i blodomlöpet | |
| DK1088084T3 (da) | Erythropoietin analog-humant serumalbumin fusionsprotein | |
| DK1427750T3 (da) | Modificerede transferrin-fusionsproteiner | |
| DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
| BR0112111A (pt) | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina | |
| EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
| DK1135498T3 (da) | Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer | |
| TR200002338T2 (tr) | Stratejik olarak yenilenmiş hepatit B çekirdek proteinler. | |
| DK1198250T3 (da) | FC-fusionsproteiner til forstærkning af protein- og peptidantigeners immunogenicitet | |
| DK1268766T3 (da) | Forbedringer af ribosom-display | |
| WO2003065003A3 (en) | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof | |
| ATE296312T1 (de) | Metalkomplexbildner | |
| MX9602557A (es) | Proteinas de higado de mamifero y su uso en oncologia. | |
| ES2114547T3 (es) | Anticuerpos monoclonales contra el virus de la hepatitis c. | |
| ATE312846T1 (de) | Monoklonale antikörper gegen hepatitis b virus | |
| ATE452650T1 (de) | Transferrin-fusionsproteinbibliotheken | |
| DE60027581D1 (de) | Design von immunogene | |
| BRPI0204599B8 (pt) | kit para a detecção simultânea de anticorpo para hcv e antígeno de hcv | |
| ATE220409T1 (de) | Rückgewinnung von proteinen durch fällung mit ligninsulfonate | |
| ES2074707T3 (es) | Anticuerpos monoclonales que distinguen entre proteinas naturales y proteinas con secuencias modificadas. | |
| De Martelaere et al. | Human osteosarcoma derived clonal variants: Stable differences in cell surface composition | |
| BR9801168A (pt) | Peptìdios de complexo de tlp de carcinoma urogenital e os seus anticorpos. |